May 16-18, 2023
Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at 22nd Annual Bio-IT World Conference & Expo taking place May 16-18, 2023, in Boston, MA.
Ai-Driven Drug Development Summit
April 26-27, 2023
Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London.
AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)
AACR (American Association of Cancer Research) Annual Meeting
April 14-19, 2023
Biolexis management participates and presents at the AACR (American Association of Cancer Research) Annual Meeting on April 14-19, 2023 – Orange County Convention Center, Orlando, Florida.
AACR 2022 Annual Meeting
April 8-13, 2023
Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.
2023 Annual San Antonio Drug Discovery Symposium
April 10-11, 2023
Biolexis Therapeutics CSO invited to present company MolecuLern™ technology at 2023 Annual San Antonio Drug Discovery Symposium held at Greehey Children’s Cancer Research Institute of University of Texas Health San Antonio.
https://research.utsa.edu/events/2023/04/03-cidd-annual-drug-discovery-symposium.html
AACR (American Association of Cancer Research) Annual Meeting
April 8-13, 2023
Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.
B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)
Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.
Next Generation Kinase Inhibitors Summit
February 22-23, 2023
Biolexis Therapeutics Business Development team participated 2nd Next Generation Kinase Inhibitors Summit was held on February 22-23, 2023, in Boston.
Precision in Drug Discovery & Preclinical Summit 2022
November 14-15, 2022
Biolexis Therapeutics Management participates and presents their MolecuLern technology at Precision in Drug Discovery & Preclinical Summit 2022 on Nov 14-15, 2022, San Francisco CA, US.
10th Annual Drug Discovery Strategic Summit
Oct 27-28, 2023
Biolexis Therapeutics Management participates and presents their MolecuLern technology at 10th Drug Discovery Strategic Summit, Oct 27th – 28th 2022, San Francisco CA, US
RESI Conference (Redefining Early-Stage Investments)
September 21-22, 2022
Biolexis Therapeutics Business Development Director Kyle Medley participated in RESI Conference (Redefining Early-Stage Investments), Boston, MA on Sep 21-22, 2022.